Avantor, Inc. (NYSE:AVTR) Shares Sold by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans lowered its holdings in Avantor, Inc. (NYSE:AVTR) by 9.1% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,274,675 shares of the company’s stock after selling 329,558 shares during the period. Thrivent Financial for Lutherans owned approximately 0.48% of Avantor worth $84,715,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the stock. Swedbank AB purchased a new position in Avantor during the 1st quarter worth approximately $2,707,000. Sound Shore Management Inc. CT purchased a new position in Avantor in the 2nd quarter valued at $76,412,000. Seven Eight Capital LP acquired a new position in Avantor in the 2nd quarter valued at $642,000. New York State Teachers Retirement System purchased a new position in Avantor during the 3rd quarter worth $8,473,000. Finally, Allspring Global Investments Holdings LLC boosted its holdings in shares of Avantor by 35.1% in the second quarter. Allspring Global Investments Holdings LLC now owns 1,157,855 shares of the company’s stock valued at $24,547,000 after acquiring an additional 300,579 shares in the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on AVTR. Stifel Nicolaus raised their price objective on shares of Avantor from $27.00 to $28.00 and gave the company a “buy” rating in a research report on Monday, July 29th. Morgan Stanley lifted their price target on Avantor from $28.00 to $29.00 and gave the company an “overweight” rating in a research note on Monday, July 29th. Royal Bank of Canada reiterated an “outperform” rating and issued a $34.00 price objective on shares of Avantor in a research report on Thursday, September 26th. Robert W. Baird decreased their target price on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a research report on Monday, October 28th. Finally, UBS Group cut their price target on shares of Avantor from $30.00 to $29.00 and set a “buy” rating for the company in a report on Tuesday, October 8th. Three equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, Avantor has a consensus rating of “Moderate Buy” and an average target price of $27.57.

Avantor Trading Down 1.9 %

Shares of Avantor stock opened at $20.74 on Monday. Avantor, Inc. has a 1 year low of $19.11 and a 1 year high of $28.00. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.54 and a quick ratio of 1.06. The business has a 50 day moving average price of $24.52 and a 200 day moving average price of $24.00. The company has a market capitalization of $14.12 billion, a P/E ratio of 45.09, a P/E/G ratio of 2.51 and a beta of 1.35.

Insiders Place Their Bets

In other news, CAO Steven W. Eck sold 3,525 shares of Avantor stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $25.06, for a total transaction of $88,336.50. Following the completion of the sale, the chief accounting officer now directly owns 29,544 shares in the company, valued at $740,372.64. The trade was a 10.66 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.50% of the stock is currently owned by company insiders.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.